Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00761241 · ClinicalTrials.gov registry record · Phase 2
Borderline Resectable Pancreatic Cancer: Gemcitabine/Docetaxel and Oxaliplatin Based Chemo/RT
A Phase 2 study, sponsored by Benaroya Research Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
NCT00761241 is a Phase 2 study that has completed, run by Benaroya Research Institute. The registered enrollment target is 40 participants.
The verdict
NCT00761241, a Phase 2 study, has completed, sponsored by Benaroya Research Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
Study Summary
This study is being conducted to find out what effects (good and bad) that a combination of treatment with chemotherapy, radiation therapy and surgery has on you and your pancreatic cancer. The chemotherapy drugs to be used: Gemcitabine, Docetaxel, Oxaliplatin, 5-FU and alpha-interferon. The goal is to decrease the size of the tumor, so that removal by surgery can be performed. Current treatments for this stage of pancreas cancer offer less than ideal results, with little opportunity for treatment with curative intent.
Interventions
- PROCEDURE Pancreaticoduodenectomy
- DRUG Gemcitabine, Docetaxel, 5FU, Oxaliplatin
- BIOLOGICAL Alpha-interferon
- RADIATION Abdominal/pelvic radiation therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2008-09 |
| Est. Completion | 2010-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00761241
The ClinicalTrials.gov registry entry for NCT00761241 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Benaroya Research Institute, which has 28 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Pancreaticoduodenectomy is the first listed.
NCT00761241 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00761241 about?
NCT00761241 is a clinical study titled "Borderline Resectable Pancreatic Cancer: Gemcitabine/Docetaxel and Oxaliplatin Based Chemo/RT". This study is being conducted to find out what effects (good and bad) that a combination of treatment with chemotherapy, radiation therapy and surgery has on you and your pancreatic cancer. The chemotherapy drugs to be used: Gemcitabine, Docetaxel, Oxaliplatin, 5-FU and alpha-interferon. The goal is...
What is the current status of trial NCT00761241?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2008-09. Estimated completion is 2010-04.
What interventions are being tested in trial NCT00761241?
The interventions under investigation include: Pancreaticoduodenectomy (PROCEDURE), Gemcitabine, Docetaxel, 5FU, Oxaliplatin (DRUG), Alpha-interferon (BIOLOGICAL), Abdominal/pelvic radiation therapy (RADIATION).
Who is sponsoring clinical trial NCT00761241?
This trial is sponsored by Benaroya Research Institute, which has 28 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.